The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT01360710
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Registry
-
NCT01360710
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- Not reported
- Countries
- Australia
- Registry status
- Unknown status
Technical summary
Registry record NCT01360710. Randomized; triple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension
- Condition
- Abdominal Obesity
- Condition
- Hypertension
- Intervention (Drug)
- Moxonidine
- Intervention (Drug)
- Irbesartan
- Lead sponsor
- Baker Heart and Diabetes Institute
Record details
- Record id
cardio:ct-nct01360710- Content hash
a8a679e71f22b809fd12db37230fddb621abedc75977c3da020c38afed8e7a42